"La Polyclinique de Gentilly regroupe plus de 120 médecins spécialistes et une équipe de 550 professionnels. Avec 417 lits, elle assure une prise en charge chirurgicale et médicale pluridisciplinaire et dispose d'un pôle de cancérologie, d'un service des urgences, d’un centre de dialyse ainsi que d'un centre de nutrition et de l’obésité ."

During the past decade, Polyclinique de Gentilly conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 2 clinical trials were completed, i.e. on average, 13.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Polyclinique de Gentilly" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 4 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "LivaNova" with 2 trials sponsored, "UNICANCER" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Polyclinique de Gentilly" #1 collaborator was "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 1 trials as a collaborator, "Floralis" with 1 trials as a collaborator and "Groupe Francais De Pneumo-Cancerologie" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Polyclinique de Gentilly" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Metastatic Colorectal Cancer" (2 trials), "ALK Gene Mutation" (1 trials), "Advanced Non Small Cell Lung Cancer" (1 trials) and "Advanced Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Polyclinique de Gentilly" in a lesser frequency.

Most popular intervention types in "Polyclinique de Gentilly" are "Drug" (12 trials), "Other" (5 trials), "Biological" (2 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Niraparib" (2 trials), "Pertuzumab" (2 trials), "Placebo" (2 trials), "Prednisone" (2 trials) and "Trastuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Polyclinique de Gentilly" are 18 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Polyclinique de Gentilly". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Polyclinique de Gentilly, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Polyclinique de Gentilly, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".